Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00917956 · ClinicalTrials.gov registry record
Lithium in Inclusion Body Myositis (IBM)
A clinical trial of Inclusion Body Myositis, sponsored by Phoenix Neurological Associates.
- Completed
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT00917956: Completed study of Inclusion Body Myositis, sponsored by Phoenix Neurological Associates.
NCT00917956 is a study of Inclusion Body Myositis that has completed, run by Phoenix Neurological Associates. The registered enrollment target is 20 participants, below the 234-participant average among 10 other Inclusion Body Myositis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00917956, a study of Inclusion Body Myositis, has completed, sponsored by Phoenix Neurological Associates.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
IBM is the most common acquired muscle disease occurring over the age of 50. The underlying cause remains unknown and there is currently no effective treatment. Pathological studies have revealed abnormal collections of proteins in the muscle cells from patients with IBM. These include proteins called phosphorylated tau (p-tau). A similar process appears to occur in Alzheimer disease, with accumulations of p-tau developing in brain cells. Lithium decreases the activity of the GSK, an enzyme that has a key role in the development of p-tau. Lithium and other GSK inhibitors have been shown to decrease the accumulation of p-tau in nerve cells in animal models of Alzheimer disease. The proposed research is a pilot study to see if lithium might be an effective treatment for IBM
Conditions Studied
Study Locations (1)
Arizona
- Phoenix Neurological Associates, LTD - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-12 |
What the finished NCT00917956 record still lists
NCT00917956 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 234-participant average among 10 other Inclusion Body Myositis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Inclusion Body Myositis appearing as the primary indexed condition, and to 0 interventions.
NCT00917956 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT00917956 about?
NCT00917956 is a clinical study titled "Lithium in Inclusion Body Myositis (IBM)". IBM is the most common acquired muscle disease occurring over the age of 50. The underlying cause remains unknown and there is currently no effective treatment. Pathological studies have revealed abnormal collections of proteins in the muscle cells from patients with IBM. These include proteins call...
What is the current status of trial NCT00917956?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2008-06. Estimated completion is 2009-12.
What conditions does trial NCT00917956 study?
This clinical trial studies the following conditions: Inclusion Body Myositis.
Who is sponsoring clinical trial NCT00917956?
This trial is sponsored by Phoenix Neurological Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00917956 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inclusion Body Myositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00917956's enrollment target sits among peer trials
20 7th of 10 higher than 2 of 10 other Inclusion Body Myositis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inclusion Body Myositis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Adult and Juvenile Myositis
RECRUITING
-
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
RECRUITING
-
Sporadic Inclusion Body Myositis Natural History Study
ACTIVE NOT RECRUITING
-
Phase III Trial of Sirolimus in IBM
ACTIVE NOT RECRUITING · Phase 3
-
Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia